Lanthanum Carbonate Patent Expiration

Lanthanum Carbonate is Used for lowering serum phosphate levels in patients with end stage renal disease. It was first introduced by Takeda Pharmaceuticals Usa Inc in its drug Fosrenol on Oct 26, 2004. 4 different companies have introduced drugs containing Lanthanum Carbonate.


Lanthanum Carbonate Patents

Given below is the list of patents protecting Lanthanum Carbonate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Fosrenol US5968976 Pharmaceutical composition containing selected lanthanum carbonate hydrates Oct 26, 2018

(Expired)

Takeda Pharms Usa
Fosrenol US7381428 Stabilized lanthanum carbonate compositions Aug 26, 2024 Takeda Pharms Usa
Fosrenol US7465465 Pharmaceutical formulation comprising lanthanum compounds Aug 26, 2024 Takeda Pharms Usa
Fosrenol US8980327 Capsule and powder formulations containing lanthanum compounds Dec 01, 2030 Takeda Pharms Usa
Fosrenol US9023397 Capsule and powder formulations containing lanthanum compounds Dec 01, 2030 Takeda Pharms Usa


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Lanthanum Carbonate Generics

Several generic applications have been filed for Lanthanum Carbonate. The first generic version for Lanthanum Carbonate was by Natco Pharma Ltd and was approved on Aug 11, 2017. And the latest generic version is by Barr Laboratories Inc A Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc and was approved on Jan 27, 2022.

Given below is the list of companies who have filed for Lanthanum Carbonate generic.


1. BARR

Barr Laboratories Inc A Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Lanthanum Carbonate. Given below are the details of the strengths of this generic introduced by Barr.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 750MG BASE tablet, chewable Prescription ORAL AB Jan 27, 2022
EQ 500MG BASE tablet, chewable Prescription ORAL AB Jan 27, 2022
EQ 1GM BASE tablet, chewable Prescription ORAL AB Jan 27, 2022


2. INVAGEN PHARMS

Invagen Pharmaceuticals Inc has filed for 3 different strengths of generic version for Lanthanum Carbonate. Given below are the details of the strengths of this generic introduced by Invagen Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 1GM BASE tablet, chewable Prescription ORAL AB Jan 24, 2022
EQ 500MG BASE tablet, chewable Prescription ORAL AB Jan 24, 2022
EQ 750MG BASE tablet, chewable Prescription ORAL AB Jan 24, 2022


3. NATCO PHARMA LTD

Natco Pharma Ltd has filed for 3 different strengths of generic version for Lanthanum Carbonate. Given below are the details of the strengths of this generic introduced by Natco Pharma Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 500MG BASE tablet, chewable Prescription ORAL AB Aug 11, 2017
EQ 750MG BASE tablet, chewable Prescription ORAL AB Aug 11, 2017
EQ 1GM BASE tablet, chewable Prescription ORAL AB Aug 11, 2017